Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was founded in 2002 and listed on NASDAQ in 2006 with an IPO. It was formerly known as Catalyst Pharmaceutical Partners, Inc. and was changed to its current name in May 2015. Headquarters Located in Coral Gables, Florida, USA, with 21 full-time employees, it is a biopharmaceutical company focused on the development and commercialization of therapeutic products for people suffering from rare debilitating, chronic neuromuscular and neurological diseases.
Catalyst Pharmaceuticals (CPRX):
Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida. The company is developing treatments for rare neurological diseases, including ampicillin phosphate, for the treatment of Lambert-Eaton myasthenia syndrome (LEMS), under the trade name “Firdapse”; and CPP-115 (a GABA transaminase) For the treatment of infantile spasms.
Catalyst Pharmaceuticals products and candidate products include:
- Firdapse, a proprietary ampicillin phosphate, has completed a phase III clinical trial for the treatment of patients with lambert-eaton myasthenia syndrome; a phase III clinical trial is also underway to treat congenital myasthenia syndrome Firdapse is currently undergoing phase III clinical trials for the treatment of anti-MuSK antibody-positive myasthenia gravis; and phase II clinical trials for patients with spinal muscular atrophy type 3.
- The company is also developing CPP-115, a γ-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms.
- CPP-109, a vigabatrin tablet.
Catalyst Pharmaceuticals, Inc. has license agreements with Northwestern University, New York University, Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.